The insensitivities of the salivary gland tumors or tumor cells to cetuximab treatment were not due to the lack of activity of the cetuximab we used, since cetuximab partially inhibited EGF-induced ERK/AKT phosphorylation in serum-starved tumor cells (Supplementary Fig. S8D). The gene discussed is AKT1; the disease is neoplasm.